Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Key Terms
respiratory syncytial virusmedical
Respiratory syncytial virus (RSV) is a common virus that infects the lungs and breathing passages, often causing cold-like symptoms in adults and more severe illness in infants, older adults, and people with weakened immune systems. Investors watch RSV because waves of infection drive demand for vaccines, treatments and hospital care the way seasonal flu does, affecting drug sales, clinical trial activity, healthcare costs and regulatory attention.
stat6 inhibitormedical
A STAT6 inhibitor is a drug or compound that blocks the action of STAT6, a protein inside cells that acts like a light switch to turn on genes involved in allergic and type‑2 immune responses (for example in asthma, eczema and some nasal polyps). For investors, these drugs matter because they target diseases with large patient populations; their clinical trial results, safety profile and regulatory approval prospects can strongly affect a biotech company’s value.
phase 2 trialmedical
A phase 2 trial is an intermediate-stage clinical study that tests whether a new treatment works and is reasonably safe in a group of patients who have the condition it targets. Think of it as a field test of a prototype product: it checks real-world effectiveness and side effects on a modest number of users to decide whether the treatment should move to larger, definitive testing. Investors watch phase 2 results because positive outcomes can sharply increase the likelihood of regulatory approval and future sales, while failures often halt development.
double-blindmedical
A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.
placebo-controlledmedical
"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.
th2 inflammationmedical
Th2 inflammation is an immune reaction driven by a subset of helper T cells that prompts allergic-type responses in tissues such as the lungs, skin and nose, often involving elevated allergy-linked white blood cells and immune signaling molecules. Investors watch it because many medications and diagnostics aim to reduce this specific pathway — successful trial results or approvals can translate into large market opportunities, much like repairing a malfunctioning sprinkler to prevent recurring damage.
alveolar macrophagemedical
A type of immune cell that lives in the tiny air sacs of the lungs and acts like a microscopic custodian, engulfing dust, germs and damaged cells to keep airways clear. Investors should care because these cells influence how well inhaled drugs, vaccines and respiratory therapies work and how the lungs respond to pollution or infection; understanding their role helps assess safety, efficacy and market potential for pulmonary products.
drug–drug interactionmedical
When two or more medicines change each other’s effects when taken together, causing one drug to work too strongly, too weakly, or to cause unexpected side effects. Think of it like mixing two recipes that alter the final flavor and safety: these interactions matter to investors because they can affect a drug’s safety profile, market acceptance, clinical trial results, regulatory approvals, labeling, and ultimately sales and liability risk.
WATERTOWN, Mass.--(BUSINESS WIRE)--
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS)International Conference 2026being held May 15-20, 2026 in Orlando, Florida.
Details of the presentations are as follows:
Title: Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial
Abstract Number: 12336
Session C96: Lung-Specific Immunity in Viral Infection: From Real-Time Host Responses to Novel Antiviral Strategies
Session Type: Mini Symposium
Date and Time: Tuesday, May 19, 2026, from2:15 PM – 2:27 PM EDT
Presenter: Christopher Harris, M.D.
Title: EPS-3903 is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in a House Dust Mite-Induced Asthma Mouse Model
Poster Number: P72
Session C34: Asthma Unveiled: A Thematic Journey from Omics to Precise Characterization of Phenotype and Therapies
Session Type: Thematic Poster Session
Date and Time: Tuesday, May 19, 2026, from11:30 AM – 1:15 PM EDT
Presenter: Yaohui Nie, Ph.D.
Title: EPS-3903, a Potent, Oral STAT6 Inhibitor, Exhibits Preferential Lung and Alveolar Macrophage Distribution with Low Drug–Drug Interaction Potential for the Treatment of Asthma
Poster Number: P75
Session Type: Thematic Poster Session
Session C34: Asthma Unveiled: A Thematic Journey from Omics to Precise Characterization of Phenotype and Therapies
Date and Time: Tuesday,May 19, 2026, from11:30 AM – 1:15 PM EDT
Presenter: Lisha Xu and Yang Li, Ph.D.
Further information about ATS 2026 can be found here. Presentations will be available on the Company’s website here following each presentation.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
